Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracer shows promise for spotting myeloma bone lesions

NCT ID NCT03891914

Diagnosis Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (FCH)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks. The goal is to find a more accurate, one-stop imaging method for initial staging and treatment monitoring.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
18F-choline and 18F-FDG (radiopharmaceutical tracers used in PET/CT imaging)
What this could lead to
If successful, this could lead to a more accurate imaging method for diagnosing multiple myeloma, potentially replacing the need for multiple scans.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply to all patients. The new tracer may not prove significantly better than the current standard.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

20 people

The number who actually took part.

Started

Nov 2019

Finished

Jan 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Symptomatic Multiple Myeloma on first-line treatment as defined by 2014 International Myeloma Working Group criteria * Measurable disease either by serum or urinary monoclonal protein level or by serum free light chains assay * Age \> 18 years old at time of signed consent * Beneficiary of social security insurance * Signed informed consent Exclusion Criteria: * Previous Multiple Myeloma treatment * Previous cancer with less than 5 year of complete remission (including plasmacytoma) * Chemotherapy in the 6 months preceding the inclusion * Uncontrolled diabetes mellitus * Medullary growth factor injection less than 48 hours before imaging procedures * Ongoing corticosteroid therapy, or given less than 72 hours before PET-CT imaging * Pregnant or nursing (lactating) women * Childbearing potential woman without adequate barrier contraception method (HAS criteria) * Freedom deprivated patient by judiciary or administrative decision * Patient under legal protection or unable to express its own consent * PET contraindication (known allergy to 18F-FCH or 18F-FDG or excipient) * MRI contraindication

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myeloma multiple are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myeloma multiple

Contacts and locations

Locations

  • Bordeaux University Hospital - Haut-Lévêque

    Pessac, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.